NCT06712745View on ClinicalTrials.gov

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Cancer, LungMetastasis
Interventions
RADIATION

Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)

Radiation Therapy Prescription Dose: A dose of 40-50 Gy in 5 fractions prescribed to the PTV will be used for all cases

Trial Locations (1)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Elekta Limited

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER